PARP Inhibition in Advanced Ovarian Cancer - prIME Oncology
prIME Decision Points
prIME Decision Points

PARP Inhibition in Advanced Ovarian Cancer

Integrating PARP Inhibition Into the Clinical Pathway

Not a member of My prIME? Join now for instant access.

Hear from the experts about the optimal use of PARP inhibitors (PARPi) in ovarian cancer, including optimal treatment setting, the role of biomarkers, management of adverse events, and maintenance of quality of life. This interactive case presentation will provide you with information on evidence-based treatment strategies and enable you to apply this information to patient scenarios.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



Release Date

Release Date

Oct 18, 2017

Expiration Date

Oct 18, 2018

Featured Experts

  • Jonathan Ledermann, BSc, MD, FRCPUCL Cancer Institute
    London, United Kingdom
  • Eric Pujade-Lauraine, MD, PhDCentre Hospitalier Universitaire Hôtel-Dieu
    Paris, France
  • Management of patients receiving PARPi therapy for ovarian cancer
  • Adverse event management for patients receiving PARPi therapy

This educational activity is designed for gynecologic oncologists, medical oncologists, and other healthcare providers involved in the management of patients with advanced ovarian cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe factors that impact treatment decision-making throughout the course of advanced ovarian cancer
  • Define platinum sensitivity according to current guidelines
  • Assess the role of germline and somatic BRCA testing and other biomarkers of genomic instability
  • Evaluate the role of PARP inhibitors as maintenance therapy for relapsed platinum-sensitive disease
  • Identify current and emerging settings in the clinical course of the disease for the use of PARP inhibitors
  • Identify adverse events associated with PARP inhibitors, and select appropriate strategies to help ensure patient treatment adherence and optimum quality of life

This educational activity is supported by a grant from AstraZeneca.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Disclosure Information


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.